|1.||Roh, Dae-Hyun: 3 articles (10/2015 - 06/2006)|
|2.||Yoon, Seo-Yeon: 3 articles (10/2015 - 06/2006)|
|3.||Beitz, Alvin J: 3 articles (10/2015 - 06/2006)|
|4.||Han, Ho-Jae: 3 articles (10/2015 - 06/2006)|
|5.||Lee, Jang-Hern: 3 articles (10/2015 - 06/2006)|
|6.||Kang, Suk-Yun: 2 articles (10/2015 - 06/2009)|
|7.||Kim, Hyun-Woo: 2 articles (10/2015 - 06/2006)|
|8.||Beitz, A J: 2 articles (12/2014 - 07/2008)|
|9.||Katnik, Christopher: 2 articles (10/2011 - 12/2006)|
|10.||Cuevas, Javier: 2 articles (10/2011 - 12/2006)|
|1.||Schizophrenia (Dementia Praecox)
12/01/2014 - "Sustained intrathecal treatment with the σ1 antagonist, BD-1047, attenuated CCI-induced increase in GFAP-immunoreactive astrocytes, and the treatment combined with fluorocitrate, an astrocyte metabolic inhibitor, synergistically reduced the development of MA, but not thermal hyperalgesia. "
12/01/2010 - "The BD 1047 (10, 30, 100 mg/kg) administered on postoperative days 0~5 dose-dependently suppressed both the induction of allodynia and the elevation of the spinal pERK expression in a manner comparable with that of gabapentin (100 mg/kg). "
06/01/2009 - "Moreover, this DHEAS-induced mechanical allodynia was significantly reduced by administration of the sigma-1 receptor antagonist, BD-1047 or the GABA(A) receptor agonist, muscimol. "
06/01/2009 - "The high-affinity and selective sigma(1) antagonists BD-1063, BD-1047 and NE-100, administered subcutaneously (s.c.), dose-dependently inhibited mechanical allodynia induced by capsaicin (1 microg,i.pl.), yielding ED(50) (mg/kg) values of 15.80+/-0.93, 29.31+/-1.65 and 40.74+/-7.20, respectively. "
07/01/2008 - "In another set of experiments Sig-1 R agonists further potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity and this was also reversed with BD-1047. "
06/01/2006 - "Intrathecal (i.t.) pretreatment with the selective sigma(1) receptor antagonist, BD-1047 (N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide) (10-100 nmol) dose dependently reduced formalin-induced pain behaviors in second phase, but not first phase, of the formalin test. "
10/01/2011 - "Moreover, the effects of afobazole on intracellular Ca(2+) increases triggered by acidosis and ischemia were blocked by the selective σ-1-receptor antagonists, BD 1063 and BD 1047, respectively. "
12/01/2006 - "Two sigma receptor antagonists, metaphit [1-(1-(3-isothiocyanatophenyl)-cyclohexyl)-piperidine] and BD-1047 (N-[2-3,4-dichlorophenyl)-ethyl]-N-methyl-2-(dimethylamino)ethylamine), were shown to blunt the ability of DTG to inhibit ischemia-evoked increases in [Ca(2+)](i), revealing that the effects are mediated by activation of sigma receptors and not via the actions of DTG on nonspecific targets such as N-methyl-d-aspartate receptors. "
|1.||sigma Receptors (sigma Receptor)
|3.||1- (2- (3,4- dichlorophenyl)ethyl)- 4- methylpiperazine
|4.||GABA-A Receptor Agonists
|6.||N-Methyl-D-Aspartate Receptors (NMDA Receptors)
|10.||Cocaine (Cocaine HCl)